

**DOCUMENT TITLE: All Wales Paediatric Asthma Management and Prescribing Guideline****CLOSING DATE: Friday 10 February 2023**

Please complete your personal details along with the Consultation Pro-forma **and** the Declaration of Interests form below. Please type directly into the forms and save with your initials (or other appropriate identifier) before returning to awttc@wales.nhs.uk.

Please note: Comments received during consultation are compiled in a report and considered by the development group. Each comment will be addressed and any changes to the document that are made as a result will be noted. The summary report including any comments submitted will be available upon request. Please allow three weeks from the date of final publication for the summary of consultation comments to be made available.

AWTTC reserves the right to summarise comments, where it is deemed appropriate, and to not publish comments if we consider their publication to be unlawful or otherwise inappropriate.

By submitting your comments, you are agreeing to them being used in line with the above.

Name	Alwyn Fortune
Organisation/Company	Royal Pharmaceutical Society (with input from Neonatal and paediatric pharmacists group (NPPG) and paediatric clinical lead pharmacists in Wales)

CONSULTATION PRO-FORMA

Is there anything you would like to see added to the *All Wales Paediatric Asthma Management and Prescribing Guideline* document?

Consideration to add comments around assessing maturity/ability to effectively use DPI and in particular MART regimes should be added.

Noting that good asthma control is good for environment and greener due to a reduction in pMDI salbutamol use.

Is there anything you would like to see removed from the *All Wales Paediatric Asthma Management and Prescribing Guideline* document?

Comments around the use of masks when using a Volumatic device. Some children aged 3-5 and children with learning disabilities may still need a mask

Any further comments you may have can be submitted using the table below.

Page number/section number/ line number	Comment
	Of note, throughout the guidelines, Salamol is recommended as one of the short acting beta-2 agonists (SABA) of choice. Highlighting the following from the SPC for Salamol "This medicine contains 3.7 mg of alcohol (ethanol) in each puff (metered dose) which is equivalent to 3.7 mg/32.4 mg (11.4%

	<p>w/w). <i>The amount in each puff (metered dose) of this medicine is equivalent to 1 ml beer or 1 ml wine.</i>"</p> <p>We would like to ensure the above, in terms of alcohol content when dosing in children, has been taken into consideration when recommending Salamol. From the SPC, understanding that as a SABA and being used on a when required (prn) basis, the number of doses/puffs administered during a 24-hour period could be as high as 8 for relief of acute asthma symptoms.</p>

DECLARATION OF INTERESTS

Do you have any business or personal interests that might be material and relevant to the project/document under consideration?

Yes	<input type="checkbox"/>
No	<input checked="" type="checkbox"/>

If **yes**, please give details below: